AbbVie has unveiled late-stage clinical trial data showing a sustained response to its all oral, interferon-free Viekirax-based hepatitis C regimen.
According to data from the TURQUOISE-III study, genotype 1b HCV patients with compensated liver cirrhosis given Viekirax (ombitasvir/paritaprevir/ritonavir tablets) plus Exviera (dasabuvir tablets) experienced a 100% sustained virologic response 12 weeks after treatment.
Genotype 1 is the most common form of the disease, accounting for 60% of cases, the most prevalent genotype of which is 1b (47%). Over time, chronic HCV may lead to liver complications, including compensated cirrhosis, in about 10%-20% patients.
The data, says Jordan Feld, research director and clinician scientist at the Toronto Center for Liver Disease in Toronto, Canada, show that this subset of patients has the potential “to achieve high response rates with an interferon and ribavirin-free treatment in 12 weeks”.
Viekirax plus Exviera was approved in Europe in January (for genotypes 1 and 4) and as Viekira Pak in the US (for genotype 1) late last year. The regimen competes with Gilead Science’s Harvoni, which combines the mega-blockbuster Sovaldi (sofosbuvir), a nucleotide analogue polymerase inhibitor, with the NS5A inhibitor ledipasvir, for HCV genotype 1 and 4 infection.